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Abstract
This study was undertaken to validate the relevance of Chloroquine (CQ) resistance markers pfcrt76 and pfmdr186 in an endemic area in
Tanzania. After treatment with CQ, recrudescence was distinguished from new infection by msp2 genotyping, and the number of concurrent
infections was also determined. The rate of children with recrudescent parasites at day 7 and/or day 14 amounted to a parasitological failure
rate of 22.4% using PCR. The mean multiplicity of infection at day 0 was 3.2 (n = 71). The allelic frequencies of the mutated pfcrt76
and pfmdr186 were estimated to be 92 and 77%, respectively. Both values exceeded by far the observed frequency of 14% of recrudescent
parasites as calculated on the whole analysed parasite population taking multiple infections into account. Although neither mutant allele is
of predictive value for parasitological resistance, there is evidence for a role of pfcrt76 in CQ resistance in the natural parasite population. All
wild-type pfcrt76 alleles were eliminated before day 3, after the onset of CQ treatment and no recrudescent parasite with the wild-type allele
was observed at later time points. The discrepancy between the rate of resistant parasites (14%) and the frequency of the mutant pfcrt76
allele (92%), however, indicates that other polymorphisms and other factors must be involved in CQ resistance. No selective elimination
of the pfmdr186 wild-type allele was observed. © 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Chloroquine (CQ) has long been used as first line drug for
the treatment of uncomplicated malaria tropica in Africa for
the last decades due to its affordability, efficacy and safety.
The rapid spread of CQ resistant parasites, however, has
limited its use for malaria treatment (White, 1992) and there
is an urgent need for alternatives.
The mechanism of CQ action and resistance is still a mat-
ter of investigation. CQ accumulates in the digestive vacuole
of the parasite (Yayon et al., 1984) where it is supposed
to interfere with haem detoxification (Slater and Cerami,
1992), or modifying aspartic and cysteine protease activity
(Goldberg et al., 1991) or intravesicular pH (Krogstad et al.,
1985). Resistant parasites are characterised by a reduced
amount of CQ accumulated in the food vacuole as compared
to sensitive parasites (Fitch, 1970). Two genes (pfmdr1 and
pfmdr2) homologous to the mammalian multidrug resistance
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gene (mdr) have been identified in P. falciparum (Foote and
Kemp, 1989). mdr codes for an ATP driven P–glycoprotein
pump which confers drug resistance in mammalian can-
cer cell lines (Roninson, 1987). Point mutations leading to
amino acid exchanges in pfmdr1 have been related to drug
resistance in P. falciparum (Ponnudurai et al., 1981; Foote
et al., 1990; Frean et al., 1992; Cox-Singh et al., 1995; von
Seidlein et al., 1997). Several field studies, however, failed
to show an association between pfmdr1 polymorphism and
drug resistance (Haruki et al., 1994; Bhattacharya et al.,
1997; Bhattacharya and Pillai, 1999). Recently, allelic re-
placement experiments have shown that polymorphisms in
pfmdr1 modify the sensitivity to CQ in parasites already
resistant to CQ (Reed et al., 2000). These findings indicate
that other genes might be crucial for CQ resistance. Genetic
cross experiments mapped CQ resistance to a 36 kb region
in chromosome 7 (Su et al., 1997). In this region, the genes
cg2 and cg1 displayed codon exchanges which associated
well with CQ resistance in several strains (Su et al., 1997).
Allelic replacement with cg2 and cg1 sequences from CQ
sensitive parasites, however, did not modify the degree of
resistance in a CQ resistant strain (Fidock et al., 2000a).
1567-1348/02/$ – see front matter © 2002 Elsevier Science B.V. All rights reserved.
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Recent evidence points to an essential role of pfcrt for
CQ resistance, another gene within this 36 kb region in
chromosome 7 (Fidock et al., 2000b). This gene codes for
a transmembrane protein which is located in the digestive
vacuole of the parasite. A mutation in codon 76 leading to a
change from lysin to threonine has been found exclusively
in CQ resistant strains of P. falciparum. This mutation is as-
sociated with an increased acidification of the digestive vac-
uole, the compartment of CQ action (Fidock et al., 2000b).
Further evidence was also given in a epidemiological study
in Mali by Djimdé et al. (2001), where it was shown that
the pfcrt mutation was selected after CQ treatment.
The objective of this study was to assess the association
of the pfcrt76 and the pfmdr186 polymorphisms with CQ
resistance in a field trial in Tanzania. The samples derived
from a standard in vivo test series carried out in Masasi,
one of the sentinel sites for monitoring drug resistance in
Tanzania. To distinguish between recrudescence and new
infection, all samples were PCR amplified for the locus of
the merozoite surface protein 2 (msp2) (Snounou and Beck,
1998).
2. Materials and methods
2.1. Study site and study population
The study was conducted at Nagaga Health Centre in the
Masasi District of Tanzania between January and March of
1999. This district is located in the southernmost area bor-
dering Mozambique. The area under study is uniform com-
prising coastal plains with sandy soils and occasional rocky
outcrops with hilly ridges. There are numerous marshy ar-
eas which may be associated with rivers or water courses
where rice is cultivated during the long rains (March–June).
Malaria transmission is intense and perennial. Nagaga
Health Centre was randomly selected from a list of all health
centres in the district. The WHO protocol for assessment of
therapeutic efficacy of antimalarial drugs for uncomplicated
P. falciparum malaria in areas with intense transmission
was followed (World Health Organization, 1996). Children
attending the outpatient clinic between the ages of 6 and 60
months were recruited and clinically examined to rule out
other causes of fever. Axillary temperatures, weights and
blood slides for parasitaemia were taken and packed cell
volumes (PCV) were also determined. Those children meet-
ing all inclusion criteria set by World Health Organization
(1996) were enrolled and standard oral CQ treatment was
administered under supervision. All children were seen at
the hospital again on days 1 and 2 for clinical examination
and CQ administration. They were again seen on days 3
and 7 for blood slides and those with treatment failure, were
given a single dose of pyrimethamine–sulfadoxine (Fansi-
dar (Hoffmann-La Roche, Basel, Switzerland)). They were
again seen on day 14, when in addition to the clinical exam-
ination, a blood slide was made and PCV was determined.
All children were treated with CQ tablets (150 mg base
of CQ phosphate tablets, Helm Pharmaceuticals GMBH
Hamburg) with a dose of 10 mg/kg body weight on days
0 and 1 and 5 mg/kg body weight on day 2. Fansidar was
given in case of treatment failure as a single dose (1.25 mg
pyrimethamine/kg body weight). In addition, Paracetamol
tablets were also given for the first 2 days and during the
follow-up if fever was documented.
2.2. Laboratory examination
Thick and thin blood smears were made on the same slide
and stained with 5% Giemsa stain at pH 7.2 for 20 min.
Parasite density was assessed by counting the number of
asexual parasites per 200 leucocytes in the thick smear. Par-
asite numbers were converted to a count per microlitre by
assuming a standard leucocyte count of 8000/l. Species
confirmation was done by examining the thin film.
2.3. Classification of therapeutic and
parasitological responses
Using the clinical and parasitological criteria set by WHO
the therapeutic responses to CQ treatment were classified
into early treatment failure (ETF), late treatment failure
(LTF) and adequate clinical response (ACR) (World Health
Organization, 1996). The sum of the rate of ETF and LTF
was referred to as the clinical treatment failure rate. Para-
sites present at day 7 and/or day 14 after CQ treatment were
classified as recrudescent if their msp2 genotype had been
previously detected. Genotypes which were not seen before
day 7 were classified as new infections. The parasitological
resistance rate was defined as the percentage of children har-
bouring true recrudescent parasites, a more stringent indica-
tor for drug resistance than the clinical treatment failure rate.
2.4. Molecular analysis
For PCR analysis blood was collected at days 0, 3, 7
and 14 on Whatman 3 MM filter paper and DNA was ex-
tracted using the Chelex method. A piece of filter paper of
about 10 mm2 was soaked overnight in 1 ml 0.5% saponin
in PBS and subsequently washed in 1 ml PBS for 30 min at
4 ◦C. It was transferred to 200l of a preheated (100 ◦C)
5% Chelex-100 resin in sterile water, vortexed for 30 s and
boiled for 10 min at 100 ◦C. The reaction tube was cen-
trifuged twice at 10,000 g for 2 min and the supernatant was
transferred to a new tube after each centrifugation step.
msp2 analysis was carried out as described previously
(Felger et al., 1999) with 5l of the above DNA prepara-
tion. The baseline multiplicity of infection was determined
as the number of msp2 genotypes, which were detected at
day 0. For the analysis of pfmdr1 codon 86 polymorphism
2l of DNA were amplified in a volume of 50l using
a PTC-100 thermocycler (MJ Research). PCR reactions
were done with 1M of each primer (Frean et al., 1992),
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1.5 mM MgCl2, 100M dNTPs, 0.75 units Taq-Polymerase
(Gibco). The thermal profile was as follows: 94 ◦C for 30 s
(4 min 30 s at cycle 1), 48 ◦C for 1 min with an increment
of +0.2 ◦C per cycle, and 72 ◦C for 2 min (7 min at cy-
cle 40) for 40 cycles. Aliquots of 10l from each PCR
product were cleaved by 1 unit Apo I (which cleaves the
wild-type) and 1 unit Afl III (which cleaves the mutant).
For pfcrt amplification (Djimdé et al., 2001), a primary
PCR was done with 1M of primer CCGTTAATAATAAA
TACACGCAG (CRTP1) and CGGATGTTACAAAAC-
TAGTTACC (CRTP2), 2.5 mM MgCl2, 200M dNTPs
and 0.75 units Taq-Polymerase (Gibco). The thermal pro-
file was 94 ◦C for 30 s (3 min at cycle 1), 56 ◦C for 30 s,
and 60 ◦C for 1 min (3 min at cycle 45) for 45 cycles. A
volume 2l of primary PCR product were used in a 50l
nested PCR reaction with 1M of primer TGTGCTCAT-
GTGTTTAAACTT (CRTD1) and CAAAACTATAGTTA
CCAATTTTG (CRTD2), 2.5 mM MgCl2, 200M dNTPs
and 0.75 units Taq-Polymerase (Gibco). The thermal profile
was 92 ◦C for 30 s (3 min at cycle 1), 48 ◦C for 30 s, and
65 ◦C for 30 s (3 min at cycle 30) for 30 cycles yielding
a 145 bp PCR product. Aliquots were digested with 1 unit
Apo I, which cleaves the wild-type into 111 and 34 bp frag-
ments. Genomic DNA from strain 3D7 was amplified and
digested in the same way serving as control for complete
digestion. Restriction digests of both pfmdr1 and pfcrt were
analysed on 10% polyacrylamide gels.
2.5. Statistical analysis
To allow for the effects of varying multiplicity in estimates
of resistance rates, we used a non-linear statistical model to
Table 1
Multiplicity of infection, day 0 pfcrt76 genotype and clinical and parasitological outcome in patients with parasitological resistance analysed by light
microscopya
Patient Multiplicity of infection D0 pfcrt76 Clinical response Parasite response by msp2
D0 D0 + 3 Rec.
9 3 6 4 1 Mut ETF Rec. + new
45 4 6 1 – Mut ETF Rec.
55 4 4 2 – Mix ETF Rec.
61 1 1 – 1 Mut ACR New
65 1 2 1 – Wild ACR Rec.
67 9 10 10 Mix ACR Rec.
71 1 3 1 1 Mut LTF Rec. + new
75 1 1 1 – Mut LTF Rec.
81 4 4 1 – Mut LTF Rec.
83 6 6 3 – Mut LTF Rec.
87 2 2 1 – Mix LTF Rec.
107 3 4 – 1 Mut ETF New
121 3 3 3 – Mut ETF Rec.
127 3 5 4 – Mut ETF Rec.
135 3 3 1 – Mut ETF Rec.
147 4 4 2 – Mut ETF Rec.
117 ND ND ND ND ND ETF ND
131 ND ND ND ND ND LTF ND
133 ND ND ND ND ND LTF ND
137 ND ND ND ND ND ETF ND
a D0: day 0; D0+3: day 0 and 3; Rec.: recrudescent; new: new at day 7 and/or day 14; ND: not determined.
estimate the allele frequencies of resistance markers prior
to treatment. Assuming resistant parasite clones to be trans-
mitted independently of sensitive clones, the likelihood for
a sample containing no resistant clones is (1−p)n, where p
is the allele frequency for the resistance marker and n is the
multiplicity of infection of the sample. Similarly, the likeli-
hood for a sample with no wild-type clones is pn and for a
mixture of wild-type and mutant clones is 1−pn−(1−p)n.
The likelihood over the whole data set for p is computed
as the product of these likelihood over all samples, using
values of n derived from the msp2 typing.
A Markov Chain Monte Carlo algorithm (Program Win-
bugs 1.3) was used to obtain estimates and credible intervals
(Bayesian confidence intervals (CI)) for p, making use of
this likelihood, and assuming a uniform (0.1) prior distribu-
tion for p.
3. Results
Among 79 children enrolled, one was lost during
follow-up. According to the clinical and parasitological
criteria set by WHO, 54 children (69.2%) had an adequate
clinical response (ACR), 17 (21.8%) and 7 children (9.0%)
showed early and late treatment failures (ETF, LTF), respec-
tively. Thus, the clinical treatment failure rate in this study
was 31%. Parasites on day 7 post-treatment were detected
in 20 children by microscopy, amounting to a parasitolog-
ical resistance rate in the host of 25.6% (Table 1). Among
them, three had asymptomatic parasitaemia at day 7 and
were classified as ACR, 10 as ETF and 7 as LTF (Table 1).
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Fig. 1. Tracing of parasites by PCR–RFLP of msp2 alleles in two patients
(A and B) at days 0, 3 and 7. Restriction fragments after Hinf I digest were
analysed by polyacrylamide electrophoresis (10%) and ethidium bromide
staining. Patient A harboured several recrudescent and one new genotype
at day 7, patient B harboured one recrudescent and one new genotype.
msp2 analysis revealed that 12 children harboured re-
crudescent infections, two only new infections and two a
mixture of recrudescent and new infections (Fig. 1, Table 1).
In four children, parasite genotypes at day 7 and/or day
14 could not be analysed. Thus, the parasitological resis-
tance rate in the host population after the subtraction of
new infections determined by msp2 genotyping was 22.4%
(14/16× 25.6%).
The mean multiplicity of infections per child prior to CQ
treatment was 3.2 with a total number of 229 infections in
71 children. The mean multiplicity amounted to 3.5, if geno-
types newly identified at day 3 post-treatment were included
in the baseline, resulting in a total number of 248 individual
infections on day 0 and/or day 3. Among those, 35 parasite
infections were found to be recrudescent on day 7 and/or
day 14 by msp2 genotyping (Table 1), amounting to a resis-
tance rate of 14% within the parasite population.
Baseline frequencies of both resistance markers pfcrt76
(Fig. 2) and pfmdr186 (Fig. 3) were analysed. About 79%
of children carried only infections with the pfcrt76 mu-
tation, 18% had mixed infections, and only 3% had the
wild-type lysin genotype (Table 2). Both children with
Table 2
Day 0 frequencies of patients carrying wild-type, mutant and mixed pfcrt76 and pfmdr186 genotypes
pfcrt76 pfmdr186
No. of patients 71 29
Mutation 78.9% (56) 44.8% (13)
Mutation and wild-type 18.3% (13) 41.4% (12)
Wild-type 2.8% (2) 13.8% (4)
Estimated allelic frequency 0.918 (95% CI: 0.876; 0.951) 0.766 (95% CI: 0665; 0.850)
Fig. 2. Representative polyacrylamide gel of Apo I restriction digests of
amplified regions of pfcrt containing the codon 76 polymorphism. The
wild-type codon is cleaved into a 111 and a 34 bp fragment.
Fig. 3. Representative polyacrylamide gel of amplified regions from
pfmdr1 containing the codon 86 polymorphism. Each PCR product was
analysed by Apo I which cleaves the wild-type, and Afl III which cleaves
the mutant.
wild-type pfcrt76 genotype infections at day 0 cleared their
parasitaemia by day 3, one had a recrudescence on day
7 after CQ treatment, which was identified as a mutant
pfcrt76 infection already present on day 3. At days 0, 13
children (45%) harboured parasites with only the Tyrosine
pfmdr186 mutation, 12 children (41%) carried both mutant
and wild-type infections, and 4 children (14%) carried only
asparagine wild-type infections (Table 2).
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By using the multiplicity of infection the allelic frequen-
cies of pfcrt76 and pfmdr186 mutation within the parasite
population were estimated to be 92% (CI95: 88, 95%) and
77% (CI95: 67, 85%), respectively. Both values exceeded by
far the observed frequency of resistant parasites which was
14%. No difference in multiplicity of infection was found be-
tween children with sensitive and those with resistant para-
sites. There was also no increased frequency of either mutant
allele on day 0 in the population of children with recrude-
scent parasites as compared to children who cleared their
parasitaemia before day 7. Nonetheless, there was evidence
for a role of pfcrt76 in CQ resistance. If the mutant allele was
not positively selected for its frequency after CQ treatment
should not increase as compared to day 0. At a wild-type
pfcrt76 frequency of 8% (CI95: 5, 12%) we would expect be-
tween 3.5 and 8.6 pfcrt76 wild-types among the 70 parasite
clones found at day 3, but we detected none. Also, at days
7 and 14 no pfcrt76 wild-type infection was detected. This
indicates that the parasites with pfcrt76 wild-type are selec-
tively eliminated by CQ treatment and treatment selects for
mutant parasites. In contrast pfmdr186 wild-types were still
observed in at least three children bearing resistant parasites
at day 7.
4. Discussion
In our study site in Tanzania, allele frequencies of mu-
tated pfcrt76 and pfmdr186 within the parasite population
were very high before the onset of drug therapy with 92
and 77%, respectively. This corresponds to a parasitological
failure rate of 22.4% as determined by PCR. The identifica-
tion of new infections emphasises the value of tracing single
infections using genetic markers. The rate of parasitologi-
cal resistant patients of 22.4% determined by PCR would
have been overestimated by 14% using light microscopy
only.
The complete elimination of the pfcrt76 wild-type before
day 3 after the onset of CQ treatment indicates that this
mutation is under selective pressure and is involved in CQ
resistance in vivo. It is not unexpected to find the mutant
pfcrt76 allele with a frequency of over 90% in patients
prior to CQ treatment. The widespread use of CQ in the
Tanzanian population might have highly selected for CQ
resistant mutants in the parasite population. Indeed high
perennial parasite transmission rates in combination with
a high proportion of hosts treated with drugs are key fac-
tors both for the survival of a newly arisen drug resistance
mutant (Mackinnon, 1997) and its rapid spread once the
frequency has reached a threshold level (Mackinnon and
Hastings, 1998). Epidemiological modelling predicts that
with continuous drug pressure the frequency of a mutant
drug resistance gene can increase from 10 to 90% within
2–5 years in areas of intense transmission. (Mackinnon
and Hastings, 1998). Since our samples were taken only at
admission from patients with malaria, the true allelic fre-
quency in the parasite population could not be determined.
This sample set is highly selected, and we would expect a
much lower allelic frequency within the circulating parasite
population.
The relevance of the pfcrt76 point mutation for CQ re-
sistance is also supported by a field study in Mali from
an area with seasonal transmission where the mutation was
found in 40% of patients at day 0, and was selected for in
all patients with resistant parasites at day 14 post-treatment
(Djimdé et al., 2001). The high allelic frequency of 92%
for the mutant pfcrt76 allele and the comparatively low fre-
quency of resistant parasite clones of 14% indicates that ad-
ditional mutations identified in pfcrt (or in yet unidentified
genes) might also account for CQ resistance (Fidock et al.,
2000b; Djimdé et al., 2001).
We failed to find an association between the pfmdr186
mutation and CQ resistance. This is in line with other field
studies in which CQ resistance was not associated with mu-
tations in this gene (Haruki et al., 1994; Bhattacharya et al.,
1997; Bhattacharya and Pillai, 1999). Our results confirm
the hypothesis that pfmdr1 is at most a modulator of CQ
resistance (Reed et al., 2000).
In conclusion, the complete elimination of the pfcrt76
wild-type after CQ treatment gives strong evidence for the
relevance of this gene in CQ resistance in a natural parasite
population.
In our study, the mean baseline multiplicity of infection
prior to treatment was 3.2 which is in the range of other
regions in Tanzania known for their high endemicity of
malaria (Smith et al., 1999). Many studies have shown that
multiplicity varies with the season, between closely related
areas and also by age (Smith et al., 1999). But the effect
of multiple infections on resistance rates has not generally
been considered. With increasing multiplicity of infections
the proportion of patients bearing either pure mutant or
pure wild-type infections decreases and the proportion of
patients bearing mixed infections increases assuming allelic
frequencies to be independent of multiplicity (Fig. 4). The
predicted trends of an increasing multiplicity are supported
by our experimental data, however, they are less prominent
(Fig. 4). At a given gene frequency a parasite population in
individuals harbouring many parasite clones is more likely
to contain resistant clones than in individuals with only
one or a few concurrent infections (Fig. 4). in vivo tests
of resistance will thus lead to apparently higher resistance
rates in highly endemic areas, even if there is no difference
in the parasite populations. In this study, a parasitological
resistance rate of 22.4% within the host population was
determined, whereas the frequency of resistant parasites
was only 14%. In order to make resistance rates of studies
with different multiplicities of parasites fully compara-
ble allelic frequencies within the parasite population have
to be determined for each mutation of a given resistance
marker.
Hence, it is necessary to establish a genetic resistance
index (GRI), which would link the observed frequency of
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Fig. 4. Modelling the proportion of mutant and mixed pfcrt76 alleles for
different multiplicities of infections based on the calculated mutant allele
frequency of 92%. Symbols: mutant expected (—); mixture expected ( );
mutant observed (); mixture observed ().
point mutations at the community level with the observed
clinical or parasitological failure rate at the health facility
level. Such GRI would allow quantification of resistance and
would provide support in decisions concerning drug policies.
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